PYX Resources: Achieving volume and diversification milestones. Watch the video here.
Fingers crossed for a US opening Wiggly. It couldn't have been worse for AS with Brexit and covid gumming up the political works in the EU and UK and the regulators have been exposed for deficient process through imo an entrenched uneven playing field to suit dubious decision takers whose decisions should have been open to debate before actioning. All AS can do is resort to academic lectures to inform decision makers; it was not his fault the playing field favoured the opposition- fleet of foot business with ministerial ear combined with poor science and regulatory process not attuned to pandemics except where 'success' is perceived (astra zeneca vaccine)
The problems with government involvement is the communication of the departments and suggest transparency is required leading to increased efficiency and accountability. Matters such as Innova purchases and ABDX ginolis need to be open to public input and subsequent investment decision making. Post Brexit the country needs to work together not be mutually destructive within its borders.
I have used it to diversify Apre and am up with the new choice though I do think the AVCT adjustment is a nod to a maturing AVCT market which is good. I did not want to use the margin however to up the risk exposure to AVCT.
It is not a priority to get the R rate down because any LFT is unlikely to affect spread of omicron and Boris prefers people stay at work with a false negative test I should imagine as the jabs keep them mobile. I am hopeful for hua in the UK and EU even if only to save the regulators from repercussions of not awarding it.
https://www.nibsc.org/about_us/mission_and_values.aspx
https://www.nibsc.org/about_us/scientific_advisory_committee.aspx
As our servants it looks like the advisory committee should be pressured to do something about procedures and COBAS 6800/8800 systems perhaps not favourable to the spike protein/whole virus detection with affimer binder/reagent. Can imagine no proactive work here though, just fees taken for advice for MHRA to keep noses clean. They were set up to be a positive force of their own but merged with MHRA on 1/4/13 https://www.nibsc.org/about_us/latest_news/nibsc_merges_with_the_mhra.aspx
https://bioservuk.com/product/avacta-affidx-sars-cov-2-antigen-lateral-flow-test/
tick the boxes to buy. Desk top review needs to be completed at the DHSC for test to be acceptable as proof of covid or not but AffiDX is widely acknowledged by AVCT investors to be the best on the market. https://www.gov.uk/government/publications/covid-19-test-validation-approved-products
The regulators will have a lot of questions to answer if AVCT's test does the job but has been thwarted by procedure.
70% of current sales are on the continent I think I read on here implying 30% in the UK, quantity under wraps
I think I was on the Jura by the look of that post and fro memory but have you listened to this https://www.youtube.com/watch?v=NNp3b_Iv1Gg . Unfortunately I am a grumpy old man, you have to have a survival strategy! I hope the relatively new CEO is not the greedy variety. Compliments of the season.
Thanks for your reply. I am not very quick to action opportunity and wonder whether I should have switched to TEP on its latest dip and then energy prices boosting client numbers as that is another steady player but with a macro boost then. I hope GBG does follow its usual form as Bigtosh says. Compliments of the season to you.
https://www.londonstockexchange.com/news-article/GBG/director-pdmr-shareholding/15248820
Wobbly markets accounting for poor SP but GBG will still be facilitating cashless transactions. Double tops on the charts but GBG missed out on the second so due a recovery I would think.
BoJo did defer to science and scientists in top positions at Oxford mainly and got the vaccine rolling. The political clout and science which should have received as urgent an emphasis for LFTs was absent; they have their hads round it now but too late to save lives. Omicron is unlikely to push sales for AffiDX in the retail space unless mandated but should be ordered for healthcare settings.
Hopefully no tests available is heralding something and anything will be welcome and support good therapeutic, AVA6000 news.
Lecture delivered 23/11/21 https://www.youtube.com/watch?v=tG_a0P2qybE
Virus like peptide vaccines subjected to non pandemic procurement processes so a north od England company lost out. Very similar to how AVCT have lost out. Emergency use for our LFT was needed and deserved just like the Oxford–AstraZeneca COVID-19 vaccine AZD1222. 31 min to 37 min is the relevant bit for my comment but like the cut of her jib generally